Receptor Inhibitors in Acute Coronary Syndromes: What Is New on the Horizon?
Dual antiplatelet therapy with aspirin and a P2Y12 receptor inhibitor represents the cornerstone therapy for patients with acute coronary syndromes or undergoing percutaneous interventions, leading to a reduction of subsequent ischemic events. Variable response to clopidogrel has received close atte...
Saved in:
Main Authors: | Adriana Dana Oprea, Wanda M. Popescu |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2013-01-01
|
Series: | Cardiology Research and Practice |
Online Access: | http://dx.doi.org/10.1155/2013/195456 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Update on glasdegib in acute myeloid leukemia – broadening horizons of Hedgehog pathway inhibitors
by: Fersing Cyril, et al.
Published: (2022-03-01) -
Acute Coronary Syndrome Mimicking Takotsubo Cardiomyopathy or Takotsubo Cardiomyopathy Mimicking Acute Coronary Syndrome?
by: Martin Chaumont, et al.
Published: (2020-01-01) -
Prediction Model of New Onset Atrial Fibrillation in Patients with Acute Coronary Syndrome
by: Na Wu, et al.
Published: (2023-01-01) -
Approach to acute chest pain and acute coronary syndrome in adults
by: Isaac Kah Siang Ng, et al.
Published: (2024-02-01) -
Acute Coronary Syndrome: An Unusual Consequence of GERD
by: Chui Man Carmen Hui, et al.
Published: (2015-01-01)